Pharmacogenomics of warfarin: uncovering a piece of the warfarin mystery (Q37367170)

20 August 2017

1 reference

title

Pharmacogenomics of warfarin: uncovering a piece of the warfarin mystery (English)

1 reference

20 August 2017

1 reference

1 reference

Michael P Gulseth

1 reference

20 August 2017

Gloria R Grice

series ordinal

1 reference

20 August 2017

William E Dager

series ordinal

1 reference

20 August 2017

publication date

1 January 2009

1 reference

American Journal of Health-System Pharmacy

20 August 2017

published in

1 reference

20 August 2017

1 reference

20 August 2017

1 reference

20 August 2017

page(s)

123-133

1 reference

Major bleeding in outpatients treated with warfarin: incidence and prediction by factors known at the start of outpatient therapy

20 August 2017

cites work

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080127

Optimization of inpatient warfarin therapy: impact of daily consultation by a pharmacist-managed anticoagulation service

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080127

Implementing anticoagulation management by pharmacists in the inpatient setting.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080127

Effect of a centralized clinical pharmacy anticoagulation service on the outcomes of anticoagulation therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080127

Pharmacist-provided anticoagulation management in United States hospitals: death rates, length of stay, Medicare charges, bleeding complications, and transfusions

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080127

Clinical impact of bleeding in patients taking oral anticoagulant therapy for venous thromboembolism: a meta-analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080127

Major bleeding after hospitalization for deep-venous thrombosis.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080127

Initiating warfarin therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080127

Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080127

Warfarin dose and the pharmacogenomics of CYP2C9 and VKORC1 - rationale and perspectives

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080127

The pharmacogenetics of coumarin therapy.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080127

The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080127

Pharmacogenomics--drug disposition, drug targets, and side effects

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080127

Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080127

Inheritance and drug response

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080127

Influence of CYP2C9 polymorphisms, demographic factors and concomitant drug therapy on warfarin metabolism and maintenance dose

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080127

Genotypes of the cytochrome p450 isoform, CYP2C9, and the vitamin K epoxide reductase complex subunit 1 conjointly determine stable warfarin dose: a prospective study.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080127

Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080127

Different contributions of polymorphisms in VKORC1 and CYP2C9 to intra- and inter-population differences in maintenance dose of warfarin in Japanese, Caucasians and African-Americans

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080127

The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080127

Contribution of age, body size, and CYP2C9 genotype to anticoagulant response to warfarin

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080127

Relative impact of covariates in prescribing warfarin according to CYP2C9 genotype

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080127

Warfarin dosing and cytochrome P450 2C9 polymorphisms.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080127

CYP2C9 gene variants, drug dose, and bleeding risk in warfarin-treated patients: a HuGEnet systematic review and meta-analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080127

A warfarin-dosing model in Asians that uses single-nucleotide polymorphisms in vitamin K epoxide reductase complex and cytochrome P450 2C9.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080127

Genetic-based dosing in orthopedic patients beginning warfarin therapy.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080127

Influence of coagulation factor, vitamin K epoxide reductase complex subunit 1, and cytochrome P450 2C9 gene polymorphisms on warfarin dose requirements.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080127

CYP2C9 genotypes and dose requirements during the induction phase of oral anticoagulant therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080127

Association of VKORC1 and CYP2C9 polymorphisms with warfarin dose requirements in Japanese patients

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080127

CYP2C9 haplotype structure in European American warfarin patients and association with clinical outcomes

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080127

Evaluation of genetic factors for warfarin dose prediction

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080127

A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080127

Association of Vitamin K epoxide reductase complex 1 (VKORC1) variants with warfarin dose in a Hong Kong Chinese patient population

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080127

Interethnic variability of warfarin maintenance requirement is explained by VKORC1 genotype in an Asian population

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080127

Warfarin Response and Vitamin K Epoxide Reductase Complex 1 in African Americans and Caucasians

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080127

Population variation in VKORC1 haplotype structure

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080127

Use of pharmacogenetics and clinical factors to predict the maintenance dose of warfarin.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080127

A prospective, randomized pilot trial of model-based warfarin dose initiation using CYP2C9 genotype and clinical data

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080127

Prospective dosing of warfarin based on cytochrome P-450 2C9 genotype.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080127

Warfarin initiation and the potential role of genomic-guided dosing.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080127

Common VKORC1 and GGCX polymorphisms associated with warfarin dose

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080127

Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080127

The influence of sequence variations in factor VII, gamma-glutamyl carboxylase and vitamin K epoxide reductase complex genes on warfarin dose requirement

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080127

Combined genetic profiles of components and regulators of the vitamin K-dependent gamma-carboxylation system affect individual sensitivity to warfarin

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080127

Novel CYP2C9 genetic variants in Asian subjects and their influence on maintenance warfarin dose

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080127

Genotypes of vitamin K epoxide reductase, gamma-glutamyl carboxylase, and cytochrome P450 2C9 as determinants of daily warfarin dose in Japanese patients.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080127

Genetic testing for warfarin dosing? Not yet ready for prime time

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080127

Impact of age, CYP2C9 genotype and concomitant medication on the rate of rise for prothrombin time during the first 30 days of warfarin therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080127

Genetic determinants of response to warfarin during initial anticoagulation

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080127

CYP2C9 genotype-guided warfarin prescribing enhances the efficacy and safety of anticoagulation: a prospective randomized controlled study.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080127

Randomized trial of genotype-guided versus standard warfarin dosing in patients initiating oral anticoagulation

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080127

Comparison of 10-mg and 5-mg warfarin initiation nomograms together with low-molecular-weight heparin for outpatient treatment of acute venous thromboembolism. A randomized, double-blind, controlled trial.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080127

Economic consequences of venous thromboembolism following major orthopedic surgery

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080127

A multicomponent intervention to prevent major bleeding complications in older patients receiving warfarin. A randomized, controlled trial

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080127

Initiating and Maintaining Patients on Warfarin Anticoagulation: The Importance of Monitoring

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080127

A comparison of a low-dose warfarin induction regimen with the modified Fennerty regimen in elderly inpatients.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080127

Initiation of warfarin therapy in elderly medical inpatients: a safe and accurate regimen.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080127

Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080127

The potential clinical and economic outcomes of pharmacogenetics-oriented management of warfarin therapy - a decision analysis.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080127

Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080127

31 March 2020

Identifiers

DOI

10.2146/AJHP080127

1 reference

20 August 2017

1 reference